

GenScript Biotech 2017 Annual Result Presentation

April 12, 2018



Disclaimer

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS NOT PERMITTED UNDER THE LAW OF THAT JURISDICTION.

This document has been prepared by Genscript Biotech Corporation (the "Company") for a limited number of recipients and for information purposes only. The information relating to the Company, its subsidiaries and affiliates, and their respective businesses and assets contained in this document has not been independently verified. This document does not purport to provide a complete description of the matters to which it relates. Some of the information is still in draft form and will only be finalized at the time of publication of the relevant prospectuses or offering circulars of the Company. No reliance shall be made in relation to the information contained in this document. No representation, warranty or undertaking, express or implied, is or will be made in, or in relation to, and no responsibility or liability (including, without limitation, any liability in negligence) is or will be accepted by the Company, Sole Sponsor, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers, or any of their shareholders, directors, officers, employees, affiliates, advisors or representatives as to, or in relation to, this document or the accuracy, fairness, reasonableness, correctness, or completeness of the information or opinions contained herein or any other information or opinions, whether written or oral, made available to any interested party or its advisors and any liability for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document therefore is hereby expressly disclaimed. The information contained in this document should be considered in the context of the circumstances prevailing at the time and is subject to change without notice. By preparing this document, none of the Company, Sole Sponsor, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers, or any of their shareholders, directors, officers, employees, affiliates, advisors or representatives undertakes any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent.

This document contains statements that reflect the Company's current beliefs and expectations about the future as of the respective dates indicated herein. These forward-looking statements are based on a number of assumptions about the Company's operations, information currently available to the Company, and factors beyond the Company's control and are subject to significant risks and uncertainties, and, accordingly, actual results may differ materially from these forward-looking statements. The Company undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates.

This document does not constitute or form part of, and should not be construed as, an offer to sell or issue or a solicitation of an offer to purchase or subscribe for any securities of the Company nor shall there be any sale of such securities in any state or country in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country. Public offering of securities to be made in the United States must be made by means of a prospectus that may be obtained from the issuer or the selling security holder and that contains detailed information about the issuer, its management and financial statements. No securities of the Company have been, or will be, registered under the US Securities Act of 1933, as amended (the "US Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, except pursuant to a registered offering in compliance with or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and the applicable securities laws of any state or other jurisdiction of the United States. In Hong Kong, no securities of the Company may be offered to the public unless a prospectus in connection with the offering for sale or subscription of such securities has been authorized by The Stock Exchange of Hong Kong Limited for registration by the Registrar of Companies in Hong Kong under the provisions of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap.32 of the Laws of Hong Kong), and has been so registered. No part of this document shall form the basis of or be relied upon in connection with any contract, commitment or investment decision in relation thereto. Any decision to purchase any securities of the Company in any offering for sale, distribution or subscription (as the case may be) in the United States, Hong Kong or anywhere else should be made solely on the basis of information contained in the relevant prospectuses or offering circulars of the Company which will be published in due course. The recipients and readers of this document should not construe the contents of this document as legal, tax, accounting or investment advice and should consult their own financial, tax, accounting or legal advisors or other consultants in case of doubt. This document, and any further information made available to you, are highly confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed to any other person, directly or indirectly.

This document must not be copied, reproduced, distributed or passed, in whole or in part, to any other person, directly or indirectly, at any time, by any medium, in any form, for any purpose without the prior written consent of the Company, Sole Sponsor, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers. Unauthorized copying or reproduction, or redistribution of this document of any information contained herein to any person, could result in material delay to, or otherwise prejudice the success of the global offering of the Company. No part of this document may be distributed, reproduced, taken or transmitted into the United States, Canada or Japan, or to any resident thereof.

You acknowledge and represent to the Company, Sole Sponsor, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers that you are a professional investor, have the knowledge, experience and capability to conduct your own assessment of the Company and its securities and that you have conducted and will conduct your own investigation with respect to the Company and its securities and have obtained or will obtain your own independent advice relating to any investment in the securities of the Company.

By accepting delivery of this document or the information contained herein, you are deemed to represent to the Company, Sole Sponsor, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers, and their shareholders, directors, officers, employees, agents, affiliates, advisors and representatives, that you are and any person you are representing, if any, a person outside the United States within the meaning of Regulation S under the US Securities Act, or a professional investor within a category of person described in the Securities and Futures (Professional Investor) Rules (Chapter 571D of the Laws of Hong Kong).

By accepting delivery of this document or the information contained herein, you are agreeing that (i) you have read and agree to comply with the requirements of this disclaimer; (ii) you will maintain absolute confidentiality regarding this document and the information contained herein; and (iii) you will not make direct contact with (a) the Company's customers, partners or subcontractors; (b) any governmental, administrative or regulatory bodies which supervise or regulate the Company; or (c) employees of the Company in order to seek non publicly available information of the Company.

Content

> **Company Overview**

Background of the Industry

Business and Finance

Cell Therapy

Investment Highlights

Mission


Make People and Nature Healthier
through Biotechnology

Make Research Easy

Make the Best Enzyme

Bring Miracles to Life

Business Blueprint




New Area of Business Development
Generating Higher Return

Core Business Generating Cash Flow
for Future Development

GenScript Proprietary Technologies

History & Milestone



Management Team



CEO
Dr. Frank ZHANG

PhD, Duke University, 1995
Schering-Plough, 1995-2002
GenScript Co-founder, 2002



President
Ms. Sally WANG

MS, Wuhan University, 1993
Shenzhen Futian,
Environmental Protection Surveillance
Station, 1993-2000
GenScript Co-founder, 2002



VP IR
Mr. Robin MENG

Controller, Saint-Gobain, 2004-2007
CFO, Quay Magnesium, 2008-2010
VP Finance, GenScript, 2010-2017
VP IR , GenScript, 2017



CSO
Dr. Li ZHU

VP Research, Cathay Biotech, Inc.,
2006-2008
VP Strategy, GenScript, 2010

Company Overview



Positioning

- **Largest provider** of gene synthesis services globally;
- **Global provider** of life sciences research and application services and products;
- **Well recognized and trusted** provider of for synthetic biology research and application services and products;



IP & Patent

- GenScript holds **multiple IPs and know-how proprietary** technology in the area of synthetic biology;



Locations

- Key locations in **New Jersey**-USA, **Nanjing**-China, **Amsterdam**-Netherland, **Dublin**-Ireland, and **Tokyo**- Japan;



Customers

- **5,000+ customers** which includes global pharmaceutical and biotech companies, colleges and universities, research institutes, government organizations and distributors in over **100 countries**;



Employees

- over **2,100 employees** globally;¹
- Employees locate in **China, America, Europe** and **Japan**;



R&D

- Research and manufacturing facilities **globally** ;
- Three key research locations in **China, America** and **Europe**;

Content

Company Overview

> **Background of the Industry**


Business and Finance

Cell Therapy

Investment Highlights

Industry Background – Molecular Biology

The Central Dogma of Molecular Biology



Chromosome

- Human has 23 pairs of **chromosome** –men have XY chromosome while women have XX chromosome;

Histones

- chromosome is made up of DNA and proteins called **histones**. The protein tightly coils the DNA to support the chromosome's structure;

DNA

- A **gene** is a molecular unit of heredity of a living organism;
- DNA** is a polynucleotide formed from covalently linked deoxy ribonucleotide units;
- There are **four types of bases: A, T, C, G**. A pairs with T, and G pairs with C

mRNA

- mRNA** is transcribed from DNA that is used as an intermediate copy of DNA for making Protein

Protein

- Protein** is the functional large biomolecule that allows organism to grow and reproduce

From Technology to Application


Gene Synthesis

- Synthesize genes from chemicals
- Do not rely on natural source for genes
- Able to synthesize genes as designed


Gene Synthesis is one of the fundamental techniques in synthetic biology.

Synthetic Biology

The design and construction of novel biological parts, devices, and systems, and the re-design of existing, natural biological systems for purposes of improving usefulness.



to Program Cells to Become Cellular Factories...




to Make High Value Products




Synthetic Biology Development History

Synthetic Biology is the design and construction of new biological parts, devices, and systems, and the re-design of existing, natural biological systems for useful purposes.




Synthetic Biology-Research Methods




Bottom-Up : Basic molecules of life are redesigned, synthesized, assembled, and consolidated through metabolic pathways and networks, to systematically construct a brand new biological system.

Top Down: Systematically search and modify key cells, pathways, and biochemical reactions layer by layer, down to the most fundamental proteins, DNA, and RNA, in order to achieve target modification.



Synthetic Biology-Key Strategic Technology Frontier

From the synthesis and manual replacement of molecules to the mathematical model-based design and artificial assembly of complex biological system, synthetic biology has undergone a gradual learning process to the design of a life molecules.



Synthetic Biology Applications



Biofuel



- ✓ Synthetic biology technologies are widely used in biofuel generation
- ✓ The emergence of advanced conversion pathways and non-food feedstocks could unlock considerable production potential
- ✓ ~\$15 billion dollar market potential



Green chemistry



- ✓ Many of the chemical processes can be converted into biological processes, using synthetic enzymes as catalyst
- ✓ Multi-billion dollar market potential through direct cost savings and avoided liability for environmental and social impacts
- ✓ ~\$10 billion dollar market potential



Natural products



- ✓ The plant genes and pathway can be moved into bacteria and microbes by synthetic biology technologies to produce Taxol, artemisinin, isoprene rubber, saffron, vanillin, and flavor and fragrance
- ✓ ~\$10 billion dollar market potential

Synthetic Biology Application-Artemisinin Production



Traditional Method



Cultivation



Harvest



Extraction




Artemisinin


In 1972, the Chinese scientist Tu Youyou and her colleagues extracted artemisinin from the herb *artemisia apiacea* and received Nobel Prize in 2015.




Synthetic Biology Method



Cultivation



Artemisinin precursor gene



Yeast strain to synthesis Artemisinin precursor




Artemisinin

Jay Keasling's laboratory at the University of California, Berkeley has engineered both *Escherichia coli* and *Saccharomyces cerevisiae* to produce of *artemisinic acid*, a precursor to artemisinin.


Market Potential

Global Life Sciences Research Service and Product



- ❑ Increasing research and development expenditure
- ❑ Emergence of innovative facilitating platforms
- ❑ Growing demands for revolutionizing therapies for major diseases
- ❑ Applications in environmental industry


Global Drug Development Service



- ❑ Increasing demand for innovative therapeutic options
- ❑ Constraints faced by drug manufacturers – higher incentives to engage drug development service providers to reduce cost and time required for drug development process
- ❑ Access to advanced research tools and technologies


Market Potential

Enzymes Application



Industrial enzyme can be used in a **variety of industries**, such as the food processing, feed pharmaceutical, and chemical industries

Enzymes Market Breakdown



Industrial enzyme market globally totals approx. **US\$6bn**, Chinese market approx. **US\$1.5bn**.

Content

Company Overview

Background of the Industry

> **Business and Finance**

Cell Therapy

Investment Highlights


Business Overview – Branding Strategy



Bio-Science
Services and Products



Industrial Synthetic Biology
Products



Cell Therapy Development

Bio-Science Services & Products

Life sciences research services and products



Services

- Gene synthesis
- Oligonucleotide synthesis
- DNA sequencing
- Protein production
- Peptide synthesis
- Antibody development

Products

- Cloning
- Gene editing
- Proteins & Antibodies, Isolation & Analysis
- Stable cell lines

Antibody drug discovery and development



Drug Discovery Services

- Target assessment & validation
- Hit generation & lead selection
- Lead optimization
- Candidate selection

Drug Development Services

- Production cell line development
- Process development


Pioneer and Largest Gene Synthesis Supplier in World

Successful delivery of more than **900,000 genes**, successful rate **99.95%**



Digital assets management

Over **98.5%** on-time delivery



One-stop gene studio

Largest capacity at **100 million bp/month**

- ✓ *PhD-level assistants*
- ✓ *Stronger molecular biology background*
- ✓ *24H/5 connected*

Professional service assistants

Antibody Drug Discovery and Development



Industrial Enzymes Business

Food Industry



Enzymes improve product quality or production efficiency for bread, dairy, grease, wine, fruit juices, beer and other food production .

Feed Industry



Enzymes improve animal feed intake, thereby promoting animal growth while reducing emissions of excrement pollution.

Starch Industry



Enzymes are used to convert starch to different kinds of sugars such as maltose, fructose and glucose, and can be further converted to alcohol.

Industrial Enzymes


Bestzyme has established the Advanced R&D Platform and Up-to-Date Industrialization Transformation Platform in the industry, which covers the entire process from proof of concept, through R&D to commercialization production.




Gene Synthesis



Strain Construction



HT Screening



Application Tests



Refinement & Condensation




Fermentation Expression



High Quality Products



Global Presence



✓ The locations of our major operating subsidiaries:

- 🚩 Nanjing, China
- 🚩 Hong Kong
- 🚩 New Jersey, US
- 🚩 Tokyo, Japan
- 🚩 Amsterdam, Netherland
- 🚩 Dublin, Ireland
- Sales Network

Strong Sales and Marketing Team


Well trained sales and marketing specialists

- Our success is attributed to our sales and marketing teams with presence in the U.S, EU, Japan. and the PRC
- Nearly **90%** of our U.S. sales and marketing team have doctoral or master's degrees in life sciences- related discipline

Interactive online ordering system


- Customers navigate directly to our websites to browse online information of most of our services and products
- Our system allows for specification and customization of each order through the option to choose features and components from an online menu

Number of Purchase Orders¹




Global Diversified Customer Base

GLOBAL SALES-BY ORG CATEGORY 20171




GLOBAL SALES-BY REGION 20171



5,000+ customers which include global pharmaceutical and biotech companies, colleges and universities, research institutes, government organizations and distributors in over **100 countries**

Research & Development

R&D Investment (\$mm)



Over **8-12%** of company's annual revenue will be invested into R&D annually.

R&D Team and Patents

- **47 registered patents¹** and **107 pending patent¹** applications world-wide
- **4 R&D teams** serving **4 business segments** including Biotechnology Research Institute and Molecular Biology Research Institute
- Over **18% of our R&D¹** staff possess **doctoral degrees** in life sciences- related disciplines in biology, molecular biology, genetics, biological engineering, immunology, etc.

Academic Achievement

Synthetic Yeast 2.0



The Group has achieved promising results in the joint research and development effort with various international research and development institutions in the field of synthetic genomics with the aim to newly design and synthesize all 16 *saccharomyces cerevisiae* chromosomes, at the total length of 12 million base pair (Project Sc2.0). In March 2017, GenScript published promoting result on Science regarding the joint research and development in the Synthetic Yeast Genome Sc2.0 Project.

Academic Magazine



As of Dec. 31, 2017, over **27,300** international peer-reviewed high-impact journal articles had cited the use of GenScript's life sciences research and application services and products.

Capacity Expansion

GenScript Zhenjiang Capacity Expansion



- Choose Zhenjiang New District as new production base ;
- Investment and registered capital: US\$30 million (in two phases) ;
- Zhenjiang will be one of our major production base in the future while Nanjing will play the role of R&D base ;
- The new facility has come into production since August 2017 ;

Bestzymes Jinnan New Production Facility



- Covers an area of 120 acres
- fermentation capacity up to 900m³
- Annual production capacity 60,000 tons
- Fermentation types: liquid and solid
- Fermentative species include bacteria, fungi, yeast and the like
- Solid formulations including powders,

GenScript Nanjing Infrastructure Expansion



- Extend exiting R&D facility ;
- Focus on Antibody Drug Discovery & Development capability;
- Total Investment : US\$46 million ;
- Gross area: 75,674 m²
- The new facility will be launched in 2018 ;

Merge & Acquisition

On 25 December 2017, GenScript acquired 100% of entire issued shares of CustomArray. CustomArray is incorporated in the State of Washington of United States of America and is a provider of oligo pools to many of the world's leading academic and industrial organizations for applications including targeted sequencing, complex DNA libraries, synthetic biology, shRNA libraries, and CRISPR. The patented, in situ synthesis of oligonucleotide microarrays uses advanced semiconductor technology to enable the synthesis of tens of thousands of oligonucleotides simultaneously.



Custom Oligo Synthesizer



Microarrays



ElectraSense Reader



Oligo Pools

- Combinatorial library
- Mutagenesis library
- gRNA library

High-throughput Automatic Platform

- Largely improve the gene synthesis flux and cut the cost

Micro Array

- Fulfill the new emerging requirements of DNA market, such as DNA storage

2017 Financial Performance


	2017 (US\$MM)	2016 (US\$MM)	% Change
Revenue	152.6	114.7	33.0%
Gross Profit	104.6	76.2	37.3%
Gross Margin	68.5%	66.4%	
Net Profit	27.0	26.5	1.9%
Net Profit Margin	17.7%	23.1%	
Adjusted Net Profit ²	<u>35.7</u>	<u>23.3</u>	<u>53.2%</u>
Adjusted Net Profit Margin	23.4%	20.3%	
Adjusted EBITDA ¹	53.4	34.4	55.2%
Adjusted EBITDA Margin	35%	30%	

- Achieved strong revenue YoY growth of 33.0%.
- Stable gross margin ratio that maintained above 68%
- Core services (bio-science research services and products) maintained market leadership and growth momentum.
 - Revenue of bio-science research services and products amounted to US\$ US\$122.5 million, representing an increase of 13.7 %.
 - Gross profit margin varied from 66.4 % for the same period last year to 68.5 % this year, and maintained at a stable level.
 - Exerted considerable effort in simplifying the internal workflow of gene synthesis to shorten the turnaround time, enabled to maintain leadership position in gene synthesis.
- Revenue of industrial synthetic biology products increased by 68.3 % to US\$11.8 million. We have also been actively developing new products in the field of special enzymes.
- New business segments, namely Immunotherapy Treatment and Technology generated revenue of 18.3M.

1. Adjusted EBITDA=EBITDA excluding investment income/ loss, foreign currency exchange gain/loss , share-based payment expenses and listing expenses
 2. Adjusted net profit= excluding investment income/loss, foreign currency exchange gain/loss and share-based payment expenses and listing expenses


Financial Highlights

Global Reported Revenue(\$mm)




2014-2017 CAGR: **29.7%**
2016-2017 Growth : **33.0%**

Gross Profit & Gross Margin (\$mm)




2014-2017 CAGR: **33.4%**
2016-2017 Growth : **37.3%**

Adjusted Net Profit² & Net Profit Margin (\$mm)







2014-2017 CAGR: **55.5%**
2016-2017 Growth : **53.2%**

Adjusted EBITDA¹ & Adjusted EBITDA Margin (\$mm)



2014-2017 CAGR: **48.5%**
2016-2017 Growth : **55.2%**

Financial Highlights-Key Ratios



Content

Company Overview
Background of the Industry
Business and Finance
> **Cell Therapy**
Investment Highlights


Multiple Myeloma

Facts about Multiple Myeloma

- Serious Cancer of bone marrow
- Over 30,280 new cases (6.6 per 100,000 men per year) diagnosed each year in the US
- About 120,000 patients exist in the US at any one time
- Trend towards patients above the age of 55
- Still considered incurable because all available first-line therapy will eventually encounter disease resistance and unavoidable disease progress.
- 5 year survival rate in US is still < 50%





Multiple Myeloma Total Market Revenue




- The Global MM market reached \$14 Billion USD in 2016, US contributed 62% of the market, at ~8.7 Billion
- The patent of Revlimid, currently the top-selling drug used in all settings of multiple myeloma, is anticipated to expire in 2019 in the US and in 2022 in the EU5 (France, Germany, Italy, Spain, and UK)

CAR-T Technology Process




Innovative Design of CAR by Legend




All other CAR-T players



Nanjing Legend VHH multi-specific CAR



Sustained Efficacy of LCAR-B38M CAR-T Therapy



Cases as of 2017/9/18	Total	unreported response	PR	VGPR	sCR
Number	40	1	3	12	24
%	100%	2.5%	7.5%	30%	60%



As of 2017/9/18, total 71 patients have been treated,

Time since LCAR-B38M CAR-T infusion (Months)

LCAR-B38M (cont.)

Adverse Event, n (%)	Patients (N=35)
Grade ≥ 3 adverse event	2 (5.7%)
Serious adverse event	0 (0)
Fatal events excluding disease progression	0 (0)

Cytokine release syndrome (CRS)




Collaboration between Legend and Janssen




On 22 December 2017 , Legend Biotech and Janssen Biotech entered into a collaboration and license agreement.

- Global co-development, co-production and co-promotion program for **LCAR-B38M** Car-T Cell Immunotherapy Collaboration ;
- Legend received an upfront payment of **\$350 million**, and will receive additional development, production performance, regulatory and sales milestone payments;
- Profits and costs to be shared **50/50 worldwide**, exclusive of Greater China, where **70 percent to Legend** and **30 percent to Janssen**;



What's Next ... for 2018 and beyond



Content

Company Overview
Background of the Industry
Business and Finance
Cell Therapy

> **Investment Highlights**

Future Strategy



The background image shows a winding asphalt road on a hillside, leading towards a sunset over the ocean. The sky is filled with soft, golden clouds, and the sun is low on the horizon, casting a warm glow over the scene. The road curves to the right, and a guardrail is visible on the edge. The overall atmosphere is one of hope and forward-looking vision.



R&D Enhancement

Increase investment in research and development projects like cell therapy and other applications to expand our research and application service and product portfolio;



Production Capacity Expansion

Enhance production capacity to capitalize on the strong demand for our life sciences research and application services and products;



Global Market Penetration

Increase penetration into the overseas and PRC markets by expanding and strengthening our sales and marketing team;



Strategic Acquisition

Pursue strategic acquisitions and cooperation against the cutting-edge techniques to complement organic growth.

Investment Highlights

World Market Leadership

We have achieved **world market leadership** in the global gene synthesis service market with recognized stature in synthetic biology, and we offer a broad and integrated life sciences research and application service and product portfolio.

Strong Sales & Marketing Force






We maintain a **strong sales and marketing team** and operate an interactive online quotation and ordering platform to support our global sales

Experienced Management Team

We have an **experienced and professional management team** supported by a strong talent base

CAR T-Cell Therapy

We have achieved innovative breakthrough for **CAR T-Cell Immunotherapy** in clinical trial



Well Known & Trusted Brand

We are a **well-known and trusted brand** underpinned by our high quality life sciences research and application services and products

Innovative R&D Capability

We possess **strong research and development capabilities**, with a proven track record and a robust service and product pipeline

Mature Enzymes Pipelines

We have a **complete and mature enzyme production line** to serve the broad industrial market

Thanks